Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) is a clinical-stage oncology therapeutics company developing antibody-drug conjugate (ADC) cancer treatments, and its news flow reflects this focus on targeted oncology and biomarker-driven research. Company updates highlight progress across an advanced three-asset ADC portfolio targeting clinically validated proteins PTK7, MUC16 and SEZ6 in solid tumors.
Investors and observers following WHWK news will see announcements on key clinical and regulatory milestones, such as clearance of the Investigational New Drug (IND) application for the PTK7-targeted ADC HWK-007 and the submission of an IND for the MUC16-targeted ADC HWK-016. News also covers the start and design of Phase 1, multicenter, open-label trials in adults with advanced or metastatic solid tumors that are refractory to standard therapies, including initial evaluation in lung, ovarian and endometrial cancers for HWK-007 and high MUC16-expressing gynecologic cancers for HWK-016.
Whitehawk’s releases further include scientific updates, such as presentation of a real-world analysis confirming PTK7 as a broadly expressed, clinically relevant target across solid tumors at the AACR-NCI-EORTC conference, and collaboration announcements like its multi-year agreement with Tempus AI to support biomarker-driven oncology research. Corporate news items feature financial results, participation in healthcare and biotechnology investor conferences, and senior leadership appointments related to clinical development.
This WHWK news page aggregates these types of developments so readers can review regulatory updates, clinical trial progress, scientific presentations, collaborations and financial disclosures in one place. For those tracking ADC-focused oncology companies, it provides a centralized view of Whitehawk Therapeutics’ reported activities and milestones over time.
Whitehawk Therapeutics (WHWK) announced two real-world ovarian cancer analyses examining MUC16 as a treatment target and potential prognostic biomarker.
MUC16 expression remained high and largely stable after standard-of-care treatments, with less treatment-associated variation than FRα, TROP2 and NaPi2b, other antibody-drug conjugate targets. In high-grade serous ovarian carcinoma, high MUC16 expression was associated with poorer real-world overall survival, including after adjustment for clinical and molecular factors. Whitehawk said the findings support exploring HWK-016 in combinations and after prior treatment. This MUC16-directed antibody-drug conjugate, which links an antibody to a cancer drug, is in an ongoing Phase 1 trial in advanced ovarian and endometrial cancers. The analyses will be presented at IGCS 2026 in Montreal, October 1–3.
Whitehawk Therapeutics (WHWK) reported new real-world analyses at WCLC 2026 supporting protein tyrosine kinase 7 (PTK7) as a durable and clinically relevant antibody drug conjugate (ADC) target in pretreated, EGFR wild-type non-small cell lung cancer.
In EGFR wild-type lung adenocarcinoma, PTK7 expression remained largely stable after standard-of-care therapies, including chemotherapy, immunotherapy, chemoimmunotherapy and tyrosine kinase inhibitors, and showed less treatment-associated variation than late-stage ADC targets such as MET, PD-L1 and ITGB6. PTK7 expression was also consistent across tumors with or without other actionable genomic alterations. A separate analysis found PTK7 expression was not independently associated with real-world overall or progression-free survival, supporting PTK7 as a target-engagement biomarker rather than a prognostic marker, and reinforcing the rationale for Whitehawk’s PTK7-directed ADC HWK‑007, currently in Phase 1.
Whitehawk Therapeutics (WHWK) has appointed Vijay Iyengar, MD, to its Board of Directors, effective September 9, 2026.
Iyengar has more than 20 years of oncology experience building and scaling global businesses, leading strategic transactions, and guiding products from early development through commercialization. During nine years in senior leadership roles at Incyte, he helped launch five brands across eight indications, supported expansion into more than 20 countries, and was involved as annual revenue grew from about $1 billion to over $4 billion. His earlier roles include senior oncology leadership at Novartis and healthcare consulting at McKinsey & Company.
Whitehawk Therapeutics (WHWK)/b) will participate in three September 2026 healthcare investor conferences, including a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, at 1:05 PM ET.Management will hold investor meetings at the Cantor Global Healthcare Conference on September 9 and the Wells Fargo 21st Annual Healthcare Conference on September 10. The Morgan Stanley fireside chat with the CFO and CSO will be webcast live on the company’s IR website and remain available for replay for about 30 days.
Whitehawk Therapeutics (Nasdaq: WHWK) reported second quarter 2026 results, highlighting continued Phase 1 enrollment for HWK-007 and HWK-016 and plans to initiate a Phase 1 trial for HWK-206 in Q3 2026 for small-cell lung cancer and neuroendocrine tumors.
Cash, cash equivalents and short-term investments totaled $190.0 million at June 30, 2026, up from $145.7 million at year-end 2025, and are expected to fund operations into 2H 2028. In May 2026, the company completed an $87.5 million private placement.
Q2 2026 research and development expense was $12.9 million versus $48.8 million a year earlier, largely reflecting a prior-year $38.0 million upfront license fee to WuXi Biologics. Net loss narrowed to $16.6 million from $52.6 million, with no product revenue reported.
Whitehawk also entered an option agreement with Hangzhou DAC for CPT113 in up to five additional ADC programs and a global collaboration with Biocytogen to access up to five bispecific antibodies for BsADC development.
Biocytogen (SSE:688796; HKEX:02315) and Whitehawk Therapeutics (Nasdaq: WHWK) announced a global collaboration on bispecific antibody-drug conjugates (BsADC) on July 7, 2026.
Biocytogen will contribute up to five RenLite®-based bispecific antibodies, while Whitehawk will apply its ADC linker-payload technologies and may advance selected BsADCs, holding global rights if options are exercised. Biocytogen receives an upfront payment, potential milestones, and low single-digit royalties.
Whitehawk Therapeutics (Nasdaq: WHWK) presented a real-world analysis at ASCO 2026 showing seizure related homolog protein 6 (SEZ6) is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors.
Data indicate SEZ6 expression exceeds other approved and emerging ADC targets and correlates with DLL3, supporting development of SEZ6-directed ADC HWK-206, with an IND filing expected mid-2026 and a Phase 1 trial planned for Q3 2026.
Whitehawk Therapeutics (Nasdaq: WHWK) announced that President and CEO Dave Lennon, PhD, will present at the Jefferies 2026 Global Healthcare Conference in New York City on Thursday, June 4 at 8:10 AM ET.
A live and replay webcast will be available on the company’s IR website for ~30 days.
Whitehawk Therapeutics (Nasdaq: WHWK) entered an option agreement with Hangzhou DAC for access to CPT113 in up to five new, internally developed ADC programs, including possible dual‑payloads. Whitehawk keeps global rights and program control and plans multiple IND filings over the next 12‑24 months.
Phase 1 dose‑escalation trials of HWK‑007 and HWK‑016 are enrolling, with data expected in 1H 2027. External programs DXC006 and JNJ‑95437446 also use CPT113, supporting confidence in Whitehawk's ADC platform and its CBCR bioconjugation process.
Whitehawk Therapeutics (Nasdaq: WHWK) announced that President and CEO Dave Lennon, PhD, will join a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 27, 2026, at 11:00 AM ET.
A live webcast and 30-day replay will be available via the company’s investor relations website.